An observational study in Unipolar Depression, sponsored by Massachusetts General Hospital. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Massachusetts General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 319 studies in Depressive Disorder with a site in United States — 38 open to participants now, 44 under way, 2 of them phase 3. Depressive Disorder · United States.
Among the 319 studies in Depressive Disorder with a site in United States, this one is the 25th largest by enrollment of the 40 observational ones that give a count, is one of 8 that started in 2020, is one of 40 observational ones, and was the 222nd registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →38 of the 319 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Brazil and 12 more countries
Ages 18–75
Ksana Health · Sites in United States
Ages 13–24
University of California, San Diego · Sites in United States
Ages 18–65
Mayo Clinic · Sites in United States
Ages 12–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
319 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 61 · Phase 3 41 · Phase 4 34
First in 1988; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is below the median of 174 across 140 observational studies indexed under Depressive Disorder.
Median enrollment 85 across the 275 interventional studies, 149 across the 40 observational. Of the 260 that completed or were terminated, 98 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 319 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 8 studies filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
16 of the studies in Depressive Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07841483Slingshot AIAI Mental Health Tool vs. Psychoeducation Control | 2026-12 |
| NCT06508450New York UniversityA Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults | 2026-12 |
| NCT05282277University of North Carolina, Chapel HillExamining the Effects of Estradiol on Neural and Molecular Response to Reward | 2026-12-31 |
| NCT05920252Ksana HealthA Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide | 2026-12-31 |
| NCT05011864University of Texas at AustinIntegrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 319 studies in Depressive Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a longitudinal study where individual with Major Depressive Disorder (MDD) will be monitored for 12 weeks. The study aims to develop an objective, sensor-based, algorithm able to detect the presence of depression as well as predict treatment response. Measurement-based treatment is considered optimal and the development of a valid passive, objective, behavioral and biological assessment of depressive symptoms that does not rely on clinician interviews will improve monitoring and ultimately improve treatment significantly.
In this longitudinal study 100 individuals with Major Depressive Disorder (MDD) will be monitored for 12 weeks. Data will include self-report surveys, in-person assessments, physiological features derived by wearable devices and socialization and activity data derived by mobile applications. The study will utilize advanced statistical methods to integrate different sources of passive sensor-based behavioral and physiological data to develop models able to detect depression and predict treatment response.
Participants will be individuals with Major Depressive Disorder
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an observational study. There is no active treatment that is examined.
The Hamilton Depression Rating Scale (HDRS) 17-items
The HDRS-17 is a clinician-based assessment of depressive symptoms. Higher scores indicate worse symptoms. Total score can range from 0 to 53.
Time frame: Past week.
Patient Health Questionnaire 9 (PHQ-9)
The PHQ-9 is a self-report questionnaire of depressive symptoms. Total scores can vary from 0 to 27. Higher scores indicate worse depressive symptoms.
Time frame: Past 7 days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in May 2024, 51 months.
Of 54 non-industry observational studies under Depressive Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 104. This study's 51 months is above that.
Counting every sponsor, half of 57 studies reached it within 38 months; a quarter within 21 and three quarters within 104.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2024 → May 2024 and completion Nov 2024 → May 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →